1.
Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 2017, 67(1):7-30.
2.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri
R, Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016, 66(4):271-289.
3.
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman
JR, Nowak MA et al: Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer. Nature 2010, 467(7319):1114-7.
4.
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
5.
Cheng H, Long F, Jaiswar M, Yang L, Wang C, Zhou Z: Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis. Scientific Reports 2015, 5:11026.
6.
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z: Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis
containing 8252 patients. Clinica chimica acta; international journal of clinical chemistry 2018, 479:181.
7.
Li M-X, Liu X-M, Zhang X-F, Zhang J-F, Wang W-L, Zhu Y, Dong J, Cheng J-W, Liu Z-W,
Ma L et al: Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic
review and meta-analysis. International Journal of Cancer 2014, 134(10):2403-2413.
8.
Cedrés S, Martínez A, Martinez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E:
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV
non-small cell lung cancer. Clinical and Translational Oncology 2012, 14(11):864-869.
9.
Yang X, Huang Y, Feng JF, Liu JS: Prognostic significance of neutrophil-to- lymphocyte ratio in esophageal cancer: a
meta-analysis. Oncotargets & Therapy 2015, 8(default):789.
10.
Supachai R, Siriwan T, Sumonmal M, Sunamchok S, Thaovalai T: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. Journal of Gynecologic Oncology 2012, 23(4):265-273.
11.
Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, Kapp
KS, Langsenlehner T: The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in
breast cancer patients. British Journal of Cancer 2014, 110(10):2524.
12.
Nikolić I, Kukulj S, Samaržija M, Jeleč V, Žarak M, Orehovec B, Taradi I, Romić D, Kolak T, Patrlj L: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio help identify patients with
lung cancer, but do not differentiate between lung cancer subtypes. Croatian Medical Journal 2016, 57(3):287-292.
13.
Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto
S, Uemoto S: Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in
advanced pancreatic cancer patients. Cancer Medicine 2014, 3(2):406-415.
14.
Krishnan S, Vishal Rana, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Shana
Palla MS, PhD SGM, Gauri Varadhachary MD: Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma
treated with chemoradiation. Cancer 2010, 107(11):2589-2596.
15.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M: Pancreatic cancer. The Lancet 2011, 378(9791):607-620.
16.
Formica V, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pellicori S, Cereda V, Russo
A, Riondino S, Guadagni F: Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting
from oxaliplatin. Cancer Biomarkers 2016, 17(3):335.
17.
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q: Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic
Cancer Treated with Chemotherapy. Annals of Surgical Oncology 2015, 22(2):670-676.
18.
Xu ZS, Zhang FP, Zhang Y, Ou-Yang YP, Yu XW, Wang WL, Xu WJ, Luo ZQ: Prognostic role of the pre-treatment platelet-lymphocyte ratio in pancreatic cancer:
a meta-analysis. Oncotarget 2017, 8(58):99003-99012.
19.
O'Byrne KJ, Dalgleish AG: Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer 2001, 85(4):473-483.
20.
Gaida MM, Steffen TGe, Günther F, Tschaharganeh DF, Felix K, Bergmann F, Schirmacher
P, Hänsch GM: Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase-mediated
degradation of E-cadherin in pancreatic tumors. European Journal of Immunology 2012, 42(12):3369-3380.
21.
Bausch D, Pausch T, Krauss T, Hopt UT, Fernandezdelcastillo C, Warshaw AL, Thayer
SP, Keck T: Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of
the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis 2011, 14(3):235.
22.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, Verstegen NJM,
Ciampricotti M, Hawinkels LJAC, Jonkers J et al: IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015, 522:345.
23.
Salazar-Onfray F, López MN, Mendoza-Naranjo A: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine & Growth Factor Reviews 2007, 18(1):171-182.
24.
Qi C, Li B, Guo S, Wei B, Shao C, Li J, Yang Y, Zhang Q, Li J, He X: P-Selectin-Mediated Adhesion between Platelets and Tumor Cells Promotes Intestinal
Tumorigenesis in ApcMin/+ Mice. International Journal of Biological Sciences 2015, 11(6):679-687.
25.
Zhou Y, Cheng S, Fathy AH, Qian H, Zhao Y: Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive
meta-analysis of 17 cohort studies. Oncotargets & Therapy 2018, 11:1899-1908.
26.
Hasegawa S, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K,
Kobayashi S, Marubashi S: Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological
response to preoperative chemoradiotherapy in pancreatic cancer. Oncology Letters 2016, 11(2):1560-1566.
27.
Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A, Khattak MA: Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J 2014, 44(7):676-682.
28.
Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, Zoughbi
WA, Seggewies FS, Lackner C: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with
primary operable and inoperable pancreatic cancer. 2013, 109(2):416-421.
29.
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A
meta-analysis. World J Gastroenterol 2015, 21(9):2807-2815.
30.
Kishi T, Nakamura A, Itasaka S, Shibuya K, Matsumoto S, Kanai M, Kodama Y, Takaori
K, Mizowaki T, Hiraoka M: Pretreatment C-reactive protein level predicts outcome and patterns of failure after
chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology 2015, 15(6):694-700.
31.
Crown J, Casper ES, Botet J, Murray P, Kelsen DP: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced
pancreatic adenocarcinoma. J Clin Oncol 1991, 9(9):1682-1686.
32.
Van Rijswijk RE, Jeziorski K, Wagener DJ, Van Laethem JL, Reuse S, Baron B, Wils J:
Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma:
a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. Eur J Cancer 2004, 40(14):2077-2081.